Nominations for New Members for the Department of Health and Human
Services (HHS) Panel on Treatment of HIV-Infected Pregnant Women and
Prevention of Perinatal Transmission in the United States.Date: February 22, 2013Source: AIDSinfoURL: http://aidsinfo.nih.gov/contentfiles/upload/PeriGL_ReqSci.pdf
The HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission in the United States
(the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV in women and prevention of mother to child HIV transmission (PMTCT). The Panel is seeking candidates with expertise in obstetrics/gynecology and/or pharmacology, particularly with experience in pharmacology studies in pregnant women.
Panel members critically evaluate new information and prepare guideline revisions. The candidates should be recognized experts in their areas of interest with a record of publications and presentations. The successful candidates will serve a 3-year term, with potential for reappointment) beginning April or May 2013. As these guidelines are focused on the management of HIV-infected pregnant women and PMTCT for the United States, candidates should be from the United States.
The Panel is a Working Group of the Office of AIDS Research Advisory Council (OARAC) of the National Institutes of Health (NIH). The Panel is comprised of approximately 25 members who are clinicians, researchers, academicians, and HHS representatives with expertise in the management of pregnant HIV-infected women (with training in either obstetrician/gynecologists or women’s health, or nursing with expertise in women’s health) and interventions for PMTCT (such as pediatric specialists in HIV infection), as well as community representatives with knowledge of HIV infection in pregnant women and interventions for PMTCT.
The Panel meets monthly via teleconference and occasionally face-to-face to review and critically evaluate emerging scientific data relating to antiretroviral therapy in pregnant women and interventions for PMTCT to update of the Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States
, which is found at http://AIDSinfo.nih.gov
Panel members are not
compensated for their time commitment and travel support is not
provided for participation.
The nomination should include a curriculum vitae and a letter of nomination (or interest) with specific reference to how the nominee would contribute to the work of the Panel. Please submit nominations by March 22, 2013
to Lynne M. Mofenson, M.D., Executive Secretary, National Institute of Child Health and Human Development, National Institutes of Health, 6100 Executive Blvd, Room 4B11, Rockville, MD 20852, phone: 301-435-6870; email: LM65D@nih.gov